Tumor microenvironment-activated hollow vanadium-based nanoplatform for precise therapy of lung cancer through synergistically reversing cisplatin resistance

Ran, Lang; Xiao, Jianmin; Zhang, Weijie; Wang, Miaomiao; Xin, Huan; Li, Huimin; Hao, Hong; Wang, Maoyang; Wang, Xiaofei; Tian, Geng; Zhang, Guilong

doi:10.1016/j.cej.2024.149448

Chemical Engineering Journal

2024

DOI: 10.1016/j.cej.2024.149448

|View full text |Cite

Tumor microenvironment-activated hollow vanadium-based nanoplatform for precise therapy of lung cancer through synergistically reversing cisplatin resistance

Lang Ran,

Jianmin Xiao,

Weijie Zhang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

In-situ activated arsenic-molybdenum dual-prodrug nanocomplexes for glutathione-depletion enhanced photothermal/chemotherapy against triple-negative breast cancer

He,

Cheng,

Ren

et al. 2024

Chemical Engineering Journal

View full text Add to dashboard Cite

In-situ activated arsenic-molybdenum dual-prodrug nanocomplexes for glutathione-depletion enhanced photothermal/chemotherapy against triple-negative breast cancer

He,

Cheng,

Ren

et al. 2024

Chemical Engineering Journal

View full text Add to dashboard Cite

Bioorthogonal Chemistry-Guided Inhalable Nanoprodrug to Circumvent Cisplatin Resistance in Orthotopic Nonsmall Cell Lung Cancer

Tang,

Yin,

Cao

et al. 2024

ACS Nano

View full text Add to dashboard Cite

Pulmonary delivery of anticancer therapeutics has shown encouraging performance in treating nonsmall cell lung cancer (NSCLC), which is characterized by high aggressiveness and poor prognosis. Cisplatin, a key member of the family of DNA alkylating agents, is extensively employed during NSCLC therapy. However, the development of chemoresistance and the occurrence of side effects severely impede the long-term application of cisplatin-based chemotherapies. Herein, we propose a meaningful strategy to precisely treat cisplatinresistant NSCLC based on the combination of bioorthogonal chemistry with an inhalation approach. Ethacraplatin (EA-Pt), a platinum prodrug (IV), was synthesized and encapsulated in nitric oxide (NO)-containing micelles to overcome cisplatin chemoresistance. By further modifying bioorthogonal molecules in this nanoplatform (EA-Pt@M DBCO ), an improved targeting performance toward pulmonary cancerous regions is achieved after prelabeling with azide via inhalation. Upon entering acidic cancer cells, EA-Pt is swiftly released due to the pH sensitivity of bioorthogonal micelles, which enables its bifunctions to inhibit glutathione S-transferase activity and deplete intracellular glutathione, eventually reversing cisplatin resistance. Moreover, the released NO also improves the overall therapeutic outcome against NSCLC. Consequently, inhalable EA-Pt@M DBCO prelabeled by azide effectively inhibits the progression of cisplatin-resistant orthotopic NSCLC, offering a feasible nanostrategy to expand the treatment options for NSCLC.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Tumor microenvironment-activated hollow vanadium-based nanoplatform for precise therapy of lung cancer through synergistically reversing cisplatin resistance

Cited by 2 publications

References 52 publications

In-situ activated arsenic-molybdenum dual-prodrug nanocomplexes for glutathione-depletion enhanced photothermal/chemotherapy against triple-negative breast cancer

In-situ activated arsenic-molybdenum dual-prodrug nanocomplexes for glutathione-depletion enhanced photothermal/chemotherapy against triple-negative breast cancer

Bioorthogonal Chemistry-Guided Inhalable Nanoprodrug to Circumvent Cisplatin Resistance in Orthotopic Nonsmall Cell Lung Cancer

Contact Info

Product

Resources

About